… Population-relevant domains are: 1) HPV vaccination in pre-… 2) HPV vaccination in older
individuals; 3) targeted vaccination … and HPV vaccination approaches and 7) alternative vaccine …

… Further, to exclude possible prevalent cervical cancers at the date of HPV vaccination, we
used a buffer period of 1 to 5 years at 1-year intervals after the index date of HPV vaccination (…

… The most recent iteration of the preventive HPV vaccine, a nanovalent, L1-VLP vaccine, …
HPV vaccines and discuss the recent progress in the development of therapeutic HPV vaccines. …

… • We do not know how well HPV vaccination will protect against cervical cancer. Trials have
not focused on the outcome of cervical cancer because they had too few participants and did …

… , have shown promising results in decreasing HPV infection and related diseases, such …
HPV vaccines, focusing on vaccine coverage and efficacy. In addition, pan-gender vaccination …

… This review aims to offer the reader a complete and updated overview on the HPV vaccination.
The … HPV vaccines, and highlight the main characteristics of the new generation vaccines. …

… Currently available prophylactic HPV vaccines are based on virus-like particles that self-…
The first HPV vaccine was licensed in 2006. All vaccines target HPV-16 and HPV-18, types …

… ☆ In this paper, I review the main achievements in terms of HPV vaccination impact over
the … of HPV vaccine impact are highlighted, as well as the need to ensure equitable vaccine …

… Inventories of prophylactic HPV vaccines should be expanded to meet the needs of our
patients, and should, one way or another, be made affordable. Advocating for our patients means …

… the use of prophylactic HPV vaccination in patients with HPV-associated … HPV vaccination
in patients with HPV-associated disease, within the context of our contemporary view of HPV …